Szotkowski, Tomas; Szotkowska, Romana; Pikalova, Zuzana; Tichy, Tomas; Flodr, Patrik; Tichy, Martin; Houserkova, Dana; Benysek, Vladimir; Zlamalova, Nora; Ruzicka, Vaclav; Indrak, Karel
June 2007
Biomedical Papers of the Medical Faculty of Palacky University i;2007, Vol. 151 Issue 1, p113
Academic Journal
Background: Spontaneous splenic rupture (SSR) is a very rare complication described in several hundred patients, mainly as case reports. It is defined as a splenic rupture without antecedent injury. The authors of the present paper describe the only two SSR cases diagnosed at the Hemato-oncology department, coincidentally in one year. Patients: The first patient was admitted to hospital because of planned chemotherapy for relapsed hairy cell leukemia. The second was directed to the Hemato-oncology outpatient department because of anemia and painful splenomegaly diagnosed by a physician. The diagnose of hematologic malignancy (diff use large B-cell lymphoma) was determined subsequently on the basis of histological examination of the spleen. Conclusion: It is necessary to consider SSR not only in patients with known diagnosis of malignant disease but in the patients with negative anamnesis, too. The aim of the paper is to draw attention to the existence of this complication.


Related Articles

  • Hairy cell leukaemia presenting as aplastic anaemia. Dixey, J. J.; Gazzard, B. G. // Journal of the Royal Society of Medicine;May1983, Vol. 76 Issue 5, p427 

    The article presents the case of a 47-year-old patient who had hairy cell leukemia (HCL) presenting as aplastic anemia. The patient was admitted with a history of influenza-like illness and fever. Physical examination was normal with no palpable lymphadenopathy. Biopsy results demonstrated...

  • SuperGen presents positive data on Nipent in NHL.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p14 

    Reports that two studies of SuperGen Inc.'s drug Nipent, as part of combination therapy, is active in patients with low-grade B-cell non-Hodgkin's lymphoma. Approval of Nipent as a single-agent treatment for patients with hairy cell leukemia; Doses; Adverse events; Toxicity events.

  • Hairy Cell Leukemia: A Five-Year Update on Seventy-One Patients. Golomb, Harvey M.; Catovsky, Daniel; Golde, David W. // Annals of Internal Medicine;Oct83, Vol. 99 Issue 4, p485 

    Discusses the clinical study of several patients with hairy cell leukemia. Clinical features of the patients who were diagnosed of having hairy cell leukemia; Recommended initial treatment for the disease when therapy is indicated; Median survival time for patients with hairy cell leukemia.

  • My Treatment Approach to Hairy Cell Leukemia. Naik, Rahul R.; Saven, Alan // Mayo Clinic Proceedings;Jan2012, Vol. 87 Issue 1, p67 

    Hairy cell leukemia (HCL) is a rare chronic lymphoproliferative disorder characterized by circulating B cells with cytoplasmic projections, pancytopenia, splenomegaly, and a typical flow cytometry pattern. Recently, the BRAF V600E mutation was uniformly identified in one HCL series, which may...

  • TCRγδ+ cells expressing Vγ 9Vδ 2, which normally predominate the blood, are found in the spleens of patients with hairy cell leukemia. van de Corput, L; Kester, M G D; Falkenburg, J H F; Willemze, R; Kluin-Nelemans, J C // Leukemia (08876924);Jan97, Vol. 11 Issue 1, p106 

    T cell receptor γ7δ[SUP+](TCRγ7δ[SUP+]) cells are present in all lymphoid tissues, but at lower frequencies than TCRαβ[SUP+] cells. In normal spleens, they account for about 15-20% of CD3[SUP+] cells. In hairy cell leukemia (HCL), a B cell malignancy with a characteristic...

  • Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics. Henry Y Dong; James Weisberger; Zach Liu; Sorina Tugulea // American Journal of Clinical Pathology;Apr2009, Vol. 131 Issue 4, p586 

    CD103 is characteristically expressed in hairy cell leukemia (HCL), a B-lymphoproliferative disorder highly responsive to treatment with purine analogs. Other CD103+ diseases are rare and do not respond well to the same therapy, including HCL variant (HCLv) and splenic marginal zone B-cell...

  • p27Kip1 Immunostaining for the Differential Diagnosis of Small B-Cell Neoplasms in Trephine Bone Marrow Biopsies. Kremer, Marcus; Dirnhofer, Stephan; Nickl, Anna; Hoefler, Heinz; Quintanilla-Martínez, Leticia; Fend, Falko // Modern Pathology;Oct2001, Vol. 14 Issue 10, p1022 

    The distinction between mantle cell lymphoma (MCL) and other small B-cell non-Hodgkin lymphomas (NHL) is important because MCL has a more aggressive clinical course. In bone marrow (BM) biopsy specimens, this distinction can be particularly difficult. Although cyclin D1 immunostaining and...

  • Hairy Cell Leukemia. Sheldon, Jessica; Wisenor, Debra H.; Roberts, George H. // Journal of Continuing Education Topics & Issues;Apr2005, Vol. 7 Issue 2, p62 

    HCL is a rare leukemia diagnosed predominately in men greater than 50 years of age. Patients usually present with malaise and fatigue, and splenomegaly is detected upon physical examination. Peripheral blood and bone marrow may exhibit the presence of "hairy" lymphocytes. Diagnosis is based upon...

  • Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia: Utility in Detection of Minimal Residual Disease by Flow Cytometry. Muzzafar, Tariq // American Journal of Clinical Pathology;Nov2009, Vol. 132 Issue 5, p692 

    We studied CD81 expression by flow cytometry (FC) on benign precursor B cells (hematogones) and leukemic blasts in precursor B-cell acute lymphoblastic leukemia (pre-B-ALL) and established its usefulness in minimal residual disease (MRD) assays. Hematogones showed uniformly bright CD81...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics